As AZ/Oxford COVID Vaccine Suffers Another Blow, Russia’s Comes In From The Cold
Sputnik V Filed For EMA Rolling Review
Discouraging news for AstraZeneca’s vaccine as another adenovirus-based vaccine, Russia’s Sputnik V, looks to be gaining favor.
You may also be interested in...
While speculation mounts about Serum Institute being next in line for an RDIF partnership, Gland Pharma and Strides unit Stelis sign up to make COVID-19 vaccine Sputnik V. Part of the 550 million dose output tied up from India so far could be consumed domestically, but exports are a possibility as demand from European countries is set to jump.
South Africa recently decided against using AstraZeneca partner Serum Institute’s vaccine for its immunization program, given its low efficacy against the B.1.351 strain. However, certain vaccines have shown higher efficacy. Is this a sign that newer strains of SARS-CoV-2 could upset supply deals and revenue projections for some vaccines?
The drug maker played up the 85% prevention of severe disease and 100% prevention of hospitalization and death despite lower overall efficacy relative to mRNA vaccines.